3-(1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidin-4-yl)propan-1-ol | 1037754-54-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidin-4-yl)propan-1-ol
• 英文别名: 3-[1-(5-Isopropyl-[1,2,4]oxadiazol-3-yl)piperidin-4-yl]propan-1-ol；3-[1-(5-propan-2-yl-1,2,4-oxadiazol-3-yl)piperidin-4-yl]propan-1-ol
• CAS: 1037754-54-3
• 化学式: C₁₃H₂₃N₃O₂
• 分子量: 253.345
• InChiKey: BZNOIJRVXDNWSH-UHFFFAOYSA-N

物化性质

• 沸点：
  389.8±34.0 °C(Predicted)
• 密度：
  1.089±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  62.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidin-4-yl)propan-1-ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and SAR studies of bicyclic amine series GPR119 agonists

  摘要：

  We disclosed a novel series of G-protein coupled receptor 119 (GPR119) agonists based on a bicyclic amine scaffold. Through the optimization of hit compound 1, we discovered that the basic nitrogen atom of bicyclic amine played an important role in GPR119 agonist activity expression and that an indanone in various bicyclic rings was suitable in this series of compounds. The indanone derivative 2 showed the effect of plasma glucose control in oGTT and scGTT in the rodent model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.117
• 作为产物：
  描述：

  N-BOC-4-(3-羟丙基)-哌啶 在 盐酸 、 盐酸羟胺 、 碳酸氢钠 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(1-(5-isopropyl-[1,2,4]oxadiazol-3-yl)piperidin-4-yl)propan-1-ol
  参考文献：
  名称：

  Synthesis and SAR studies of bicyclic amine series GPR119 agonists

  摘要：

  We disclosed a novel series of G-protein coupled receptor 119 (GPR119) agonists based on a bicyclic amine scaffold. Through the optimization of hit compound 1, we discovered that the basic nitrogen atom of bicyclic amine played an important role in GPR119 agonist activity expression and that an indanone in various bicyclic rings was suitable in this series of compounds. The indanone derivative 2 showed the effect of plasma glucose control in oGTT and scGTT in the rodent model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.117

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：PROSIDION LTD

  公开号：WO2010103334A1

  公开（公告）日：2010-09-16

  The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及具有以下式（I）的治疗化合物，其作为GPR119的激动剂具有活性，并可用于治疗包括2型糖尿病在内的代谢紊乱。
• PIPERIDINE GPCR AGONISTS
  申请人：Bertram Lisa Sarah

  公开号：US20100022591A1

  公开（公告）日：2010-01-28

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  式(I)的化合物或其药学上可接受的盐，是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Piperidine GPCR Agonists
  申请人：Fyfe Matthew Colin Thor

  公开号：US20100048631A1

  公开（公告）日：2010-02-25

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  化合物公式（I）或其药学上可接受的盐是GPCR激动剂，可用于治疗肥胖症和糖尿病。
• Compounds for the Treatment of Metabolic Disorders
  申请人：Barba Oscar

  公开号：US20120059014A1

  公开（公告）日：2012-03-08

  The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

  本发明涉及以下式(I)的治疗化合物，其具有作为GPR119激动剂的活性，可用于治疗代谢紊乱，包括II型糖尿病。
• Piperidine GPCR agonists
  申请人：Prosidion Limited

  公开号：EP2377863A1

  公开（公告）日：2011-10-19

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

  式(I)化合物： 或其药学上可接受的盐类是 GPCR 激动剂，可用于治疗肥胖症和糖尿病。